AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2020
Dec 4, 2020
30591_dirs_2020-12-04_449c606e-bb7b-4238-b17d-f7e575f7c463.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2020-12-02
Reporting Person: BENNETT C FRANK (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-02 | Common Stock | M | 7053.0 | $39.87 | Acquired | 39529.0 | Direct |
| 2020-12-02 | Common Stock | S | 7053.0 | $51.32 | Disposed | 32476.0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-12-02 | Employee Stock Option (right to buy) | $39.87 | M | 7053.0 | Disposed | 2021-01-01 | Common Stock (0.0) | Direct |
Footnotes
F1: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.
F2: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00-$51.70, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.